J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
Vijaya Raj Bhatt,Fausto R. Loberiza,Lynette M. Smith,James O. Armitage,Timothy C. Greiner,Martin Bast,Matthew A. Lunning,Philip J. Bierman,Julie M. Vose,R. Gregory Bociek +9 more
TL;DR: The OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy, according to univariate and multivariate analysis.
Journal ArticleDOI
High-Dose Therapy/Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Marginal Zone Non-Hodgkin Lymphoma
Lanfang Li,Philip J. Bierman,Julie M. Vose,Fausto R. Loberiza,James O. Armitage,R. Gregory Bociek +5 more
TL;DR: It is concluded that HDT/AHSCT is feasible in patients who have relapsed/refractory marginal zone lymphomas and underwent high-dose therapy/autologous hematopoietic stem cell transplantation at the University of Nebraska from August 1992 to August 2008.
Journal ArticleDOI
Mitoxantrone and Fludarabine in the Treatment of Patients with Non-Hodgkin's Lymphoma Failing Primary Therapy with a Doxorubicin-or Mitoxantrone-Containing Regimen
Stephanie A. Gregory,Julie M. Vose,Manuel Modiano,Kenneth Kraemer,Robert Rifkin,Abbe Rubin,Thomas Menduni,Richard G. Ghalie +7 more
TL;DR: The combination regimen with mitoxantrone and fludarabine for recurrent lymphoma of any grade was well tolerated and objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% withCR) for Patients with low- grade NHL.
Journal ArticleDOI
Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)
Julie M. Vose,Shelly L. Carter,Linda J. Burns,Ernesto Ayala,Oliver W. Press,Craig H. Moskowitz,Edward A. Stadtmauer,Shin Mineishi,Richard F. Ambinder,Timothy S. Fenske,Mary M. Horowitz,Marcie Tomblyn +11 more
TL;DR: Patients in complete remission after salvage chemotherapy (CR2) had an improved 2-yr OS compared to patients with primary induction failure (PIF) or chemosensitive relapse (p= 0.005), however, there were no differences in any group by treatment arm.
Journal ArticleDOI
American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
Gabriel N. Hortobagyi,Doug Pyle,Eduardo Cazap,Nagi S. El Saghir,Lawrence N. Shulman,Gary H. Lyman,Lowell E. Schnipper,Clement Adebamowo,David R. Gandara,Julie M. Vose,Sandra L. Wong,Peter Paul Yu +11 more
TL;DR: Task Force findings included global concerns, such as access to care, and specific concerns of middle- and low-resource settings, and the need to strengthen health systems and the importance of alliances with a range of international cancer stakeholders were emphasized.